Cargando…

Increases survival by apo-sGC activation via post-stroke blood brain barrier stabilisation and anti-inflammation

Detalles Bibliográficos
Autores principales:	Langhauser, Friedericke, Hauck, Annegret, Radermacher, Kim, Stasch, Johannes-Peter, Kleinschnitz, Christoph, Schmidt, Harald HHW
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765608/ http://dx.doi.org/10.1186/2050-6511-14-S1-P36

Ejemplares similares

A systems biology approach to cGMP suggests a prominent role for sGC in stroke: Validation by mechanism-based activation of apo-sGC in non-steal dosing coveys neuroprotection and increased survival
por: Casas, Ana I, et al.
Publicado: (2015)

Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation/activation of sGC without hypotension
por: Jones, Emma S, et al.
Publicado: (2009)

Targeting native and apo-sGC
por: Struthers, Mary, et al.
Publicado: (2013)

Relaxant effect of BAY 41-2272 and BAY 58-2667 in the gastrointestinal tract of apo-sGC mice
por: Cosyns, Sarah, et al.
Publicado: (2011)

Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC
por: Becker-Pelster, Eva M., et al.
Publicado: (2022)

sGC redox regulation and asthma
por: Stuehr, Dennis J, et al.
Publicado: (2015)

Structural insights into sGC activation by different activators
por: van den Akker, Focco, et al.
Publicado: (2011)

sGC activators and stimulators attenuate ischemia/reperfusion injury of the lung
por: Egemnazarov, Bakytbek, et al.
Publicado: (2009)

The 1027(th) target candidate in stroke: Will NADPH oxidase hold up?
por: Radermacher, Kim A, et al.
Publicado: (2012)

Phenotypes of sGC mutant mice in basic conditions, disease and shock
por: Brouckaert, Peter, et al.
Publicado: (2009)

Mechanisms driving heme insertion into apo-sGC during its maturation in cells
por: Stuehr, Dennis, et al.
Publicado: (2013)

Structural insights into sGC
por: Akker, Focco van den, et al.
Publicado: (2009)

A combined pre-clinical meta-analysis and randomized confirmatory trial approach to improve data validity for therapeutic target validation
por: Kleikers, Pamela WM., et al.
Publicado: (2015)

NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272
por: Becker, Eva Maria, et al.
Publicado: (2001)

Molecular aspects of sGC regulation
por: Marletta, Michael A, et al.
Publicado: (2011)

Antihypertrophic actions of NO-independent soluble guanylyl cyclase (sGC) ligands BAY 41-2272 and BAY 58-2667 in vitro
por: Ritchie, Rebecca, et al.
Publicado: (2009)

Comparison of different vasodilators, endothelin antagonist, PDE5 inhibitior and sGC stimulators, in an animal model of secondary pulmonary hypertension: effects on “desaturation”
por: Becker, Eva Maria, et al.
Publicado: (2011)

New clinical results with sGC stimulators
por: Behr, Jürgen
Publicado: (2011)

Synthesis and evaluation of bifunctional sGC regulators
por: Chrominski, Mikolaj, et al.
Publicado: (2013)

Conformational changes involved in sGC activation
por: Marletta, Michael A, et al.
Publicado: (2013)

The sGC stimulator BAY 41-8543 in a rat model of hypertension-induced heart failure
por: Haase, N, et al.
Publicado: (2015)

Lack of correlation between sGC subunit expression and sGC activity in cerebral development is due to non-heterodimerizing subunits in vivo
por: Haase, Nadine, et al.
Publicado: (2009)

A Zebrafish Drug-Repurposing Screen Reveals sGC-Dependent and sGC-Independent Pro-Inflammatory Activities of Nitric Oxide
por: Wittmann, Christine, et al.
Publicado: (2015)

Synergistic mutations in soluble guanylyl cyclase (sGC) reveal a key role for interfacial regions in the sGC activation mechanism
por: Childers, Kenneth C., et al.
Publicado: (2019)

A molecular view of the regulation of sGC activity
por: Marletta, Michael A, et al.
Publicado: (2009)

Genetic modifiers of hypertension in sGC-deficient mice
por: Buys, Emmanuel
Publicado: (2013)

The clinical development of sGC modulators, riociguat and vericiguat
por: Misselwitz, Frank
Publicado: (2015)

B cells do not have a major pathophysiologic role in acute ischemic stroke in mice
por: Schuhmann, Michael K., et al.
Publicado: (2017)

New vitamin B(12) derivatives activates sGC
por: Gryko, Dorota, et al.
Publicado: (2011)

Gemfibrozil as a potential heme-independent sGC activator
por: Sobolevsky, Michael, et al.
Publicado: (2011)

Inhaled nitric oxide: an sGC-dependent IOP lowering agent
por: Lieb, Wolfgang S, et al.
Publicado: (2015)

Additional stimulation of sGC on top of standard treatment with ARB`s may offer a new therapeutic approach for the treatment of diabetic nephropathy resistant to ARB treatment alone
por: Alter, Markus, et al.
Publicado: (2011)

Dimethyl Fumarate Attenuates Lymphocyte Infiltration and Reduces Infarct Size in Experimental Stroke
por: Schuhmann, Michael K., et al.
Publicado: (2023)

Genetic silencing of sGC β1 in cancer: role of epigenetic regulation
por: Sotolongo, Alex, et al.
Publicado: (2013)

Is Innervation of the Neuromuscular Junction at the Diaphragm Modulated by sGC/cGMP Signaling?
por: Lukáčová, Nadežda, et al.
Publicado: (2020)

sGC Activity and Regulation of Blood Flow in a Zebrafish Model System
por: Vishnolia, Krishan K., et al.
Publicado: (2021)

Aortic disease in Marfan syndrome is caused by overactivation of sGC-PRKG signaling by NO
por: de la Fuente-Alonso, Andrea, et al.
Publicado: (2021)

sGC Stimulation Saves the Diabetic Heart: Red Blood Cells to the Rescue
por: Papapetropoulos, Andreas, et al.
Publicado: (2023)

Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy
por: Krishnan, Shalini Murali, et al.
Publicado: (2021)

Inflammation in the Human Periodontium Induces Downregulation of the α(1)- and β(1)-Subunits of the sGC in Cementoclasts
por: Korkmaz, Yüksel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dre6902g6uasg9ad37vghg89ua